Infinity Initiates Randomized Phase 2 Trial of IPI-504, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer
19. Mai 2011 08:02 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a Phase 2 clinical trial of retaspimycin hydrochloride (HCl), also...
Infinity Announces Clinical Data to be Presented at ASCO
19. Mai 2011 07:58 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that clinical data for IPI-926, its novel Smoothened antagonist, and retaspimycin...
Infinity Reports First Quarter 2011 Financial Results
10. Mai 2011 16:00 ET
|
Infinity Pharmaceuticals, Inc.
— Reaffirms 2011 Financial Guidance and Provides Additional Details —
— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
Infinity Announces the Date of Its First Quarter 2011 Financial Results Conference Call and Webcast
03. Mai 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, May 10, 2011 at 4:30 p.m. ET. During the call, management will...
Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development
11. April 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 11, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the appointment of Joshua D. Hamermesh as vice president, business and corporate...
Infinity Pharmaceuticals to Present at BioCentury Future Leaders Conference
07. April 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at BioCentury's 18th Annual Future Leaders in the Biotech Industry Conference on...
Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma
03. April 2011 13:36 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...
Infinity to Present New Preclinical Data on IPI-926, a Novel Smoothened Antagonist Targeting the Hedgehog Pathway, at Upcoming AACR Meeting
23. März 2011 08:01 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 23, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that the company will present new preclinical data supporting ongoing development of...
Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results
15. März 2011 16:00 ET
|
Infinity Pharmaceuticals, Inc.
IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline Momentum
Cash Runway Into 2014 Enables Advancement of Product Candidates to
Key Inflection Points
Company Changes Accounting...
Infinity Announces the Date of Its Fourth Quarter 2010 Financial Results Conference Call and Webcast
08. März 2011 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 8, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, March 15, 2011 at 4:30 p.m. ET. During the call, management...